Sickle Cell Retinopathy: a Review
Journal of Ophthalmic and Optometric Sciences,
Vol. 2 No. 1 (2018),
1 January 2018
,
Page 34-39
https://doi.org/10.22037/joos.v2i1.28578
Abstract
Sickle cell disease is one of the most prevalent hemoglobinopathies in the world. In Iran, sickle cell disease is more common in southern parts of the country such as Khuzestan province. Retinopathy is the most representative ocular complication of sickle cell disease. Sickle cell retinopathy is characterized by the vaso-occlusion of capillary beds and is classified in two types of proliferative and non-proliferative according to presence or absence of vascular proliferation in fundus. In non-proliferative sickle cell retinopathy, the retinal changes do not involve neovascularization as they do in proliferative sickle cell retinopathy. The two most severe complication of proliferative sickle cell retinopathy are vitreous hemorrhage and retinal detachment, which may lead to visual loss. Identification and prompt referral of these patients has a critical role in prevention of irreversible visual loss.
Newer imaging modalities such as ultra–wide field fluorescein angiography, spectral domain optical coherence tomography and optical coherence tomography angiography are now available. These techniques can detect the sickle cell retinopathy in its early stages.
In this review, we briefly discuss the manifestations, diagnosis and management of sickle cell retinopathy.
keywords: Anemia; Sickle Cell; Retinopathy; Diagnosis; Management; Iran.
How to Cite
References
Wastnedge E, Waters D, Patel S, Morrison K, Goh MY, Adeloye D, et al. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob Health. 2018;8(2):021103.
Rezaei N, Naderimagham S, Ghasemian A, Saeedi Moghaddam S, Gohari K, Zareiy S, et al. Burden of Hemoglobinopathies (Thalassemia, Sickle Cell Disorders and G6PD Deficiency) in Iran, 1990-2010: findings from the Global Burden of Disease Study 2010. Arch Iran Med. 2015;18(8):502-7.
Marengo-Rowe AJ. Structure-function relations of human hemoglobins. Proc (Bayl Univ Med Cent). 2006;19(3):239–45.
Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. Environmental determinants of severity in sickle cell disease. Haematologica. 2015;100(9):1108-16.
Menaa F, Khan BA, Uzair B, Menaa A. Sickle cell retinopathy: improving care with a multidisciplinary approach. J Multidiscip Healthc. 2017;10:335-46.
Ilesanmi OO. Pathological basis of symptoms and crises in sickle cell disorder: implications for counseling and psychotherapy. Hematol Rep. 2010;2(1):e2.
Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009;84(9):618-25.
Sparkenbaugh E, Pawlinski R. Prothrombotic aspects of sickle cell disease. J Thromb Haemost. 2017;15(7):1307-16.
Chaturvedi S, DeBaun MR. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years. Am J Hematol. 2016 ;91(1):5-14.
Elagouz M, Jyothi S, Gupta B, Sivaprasad S. Sickle cell disease and the eye: old and new concepts. Surv Ophthalmol. 2010;55(4):359-77.
de Melo MB. An eye on sickle cell retinopathy. Rev Bras Hematol Hemoter. 2014;36(5):319-21.
Bonanomi MT, Lavezzo MM. Sickle cell retinopathy: diagnosis and treatment. Arq Bras Oftalmol. 2013 Oct;76(5):320-7.
Fadugbagbe AO, Gurgel RQ, Mendonça CQ, Cipolotti R, dos Santos AM, Cuevas LE. Ocular manifestations of sickle cell disease. Ann Trop Paediatr. 2010;30(1):19-26.
Ribeiro MVMR, Jucá JVO, Alves ALCDS, Ferreira CVO, Barbosa FT, Ribeiro ÊAN. Sickle cell retinopathy: A literature review. Rev Assoc Med Bras (1992). 2017;63(12):1100-3.
Friberg TR, Young CM, Milner PF. Incidence of ocular abnormalities in patients with sickle hemoglobinopathies. Ann Ophthalmol. 1986;18(4):150-3.
Liem RI, Calamaras DM, Chhabra MS, Files B, Minniti CP, Thompson AA. Sudden-onset blindness in sickle cell disease due to retinal artery occlusion. Pediatr Blood Cancer. 2008;50(3):624-7.
Abdalla Elsayed MEA, Mura M, Al Dhibi H, Schellini S, Malik R, Kozak I, et al. Sickle cell retinopathy. A focused review. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1353-64.
Rosenberg JB, Hutcheson KA. Pediatric sickle cell retinopathy: correlation with clinical factors. J AAPOS. 2011;15(1):49-53.
Leveziel N, Bastuji-Garin S, Lalloum F, Querques G, Benlian P, Binaghi M, et al. Clinical and laboratory factors associated with the severity of proliferative sickle cell retinopathy in patients with sickle cell hemoglobin C (SC) and homozygous sickle cell (SS) disease. Medicine (Baltimore). 2011;90(6):372-8.
Lim JI. Ophthalmic manifestations of sickle cell disease: update of the latest findings. Curr Opin Ophthalmol. 2012;23(6):533-6.
Goldberg MF. Classification and pathogenesis of proliferative sickle retinopathy. Am J Ophthalmol. 1971; 71(3):649-65.
Pahl DA, Green NS, Bhatia M, Lee MT, Chang JS, Licursi M, et al. Optical Coherence Tomography Angiography and Ultra-widefield Fluorescein Angiography for Early Detection of Adolescent Sickle Retinopathy. Am J Ophthalmol. 2017;183:91-8.
Chalam KV, Sambhav K. Optical Coherence Tomography Angiography in Retinal Diseases. J Ophthalmic Vis Res. 2016;11(1):84-92.
Murthy RK, Grover S, Chalam KV. Temporal macular thinning on spectral-domain optical coherence tomography in proliferative sickle cell retinopathy. Arch Ophthalmol. 2011;129:247-9.
Leitão Guerra RL, Leitão Guerra CL, Bastos MG, de Oliveira AHP, Salles C. Sickle cell retinopathy: What we now understand using optical coherence tomography angiography. A systematic review. Blood Rev. 2019;35:32-42.
Goldberg MF. Treatment of proliferative sickle retinopathy. Trans – Am Acad Ophthalmol Otolaryngol Am Acad Ophthalmol Otolaryngol. 1971;75:532-56.
Do BK, Rodger DC. Sickle cell disease and the eye. Curr Opin Ophthalmol. 2017;28(6):623-8.
Scott AW. Ophthalmic Manifestations of Sickle Cell Disease. South Med J. 2016;109(9):542-8.
Russo G, De Franceschi L, Colombatti R, Rigano P, Perrotta S, Voi V, et al. Current challenges in the management of patients with sickle cell disease - A report of the Italian experience. Orphanet J Rare Dis. 2019;14(1):120.
Okonkwo ON, Lewis K, Hassan AO, Gyasi ME, Oluyadi B, Ogunro A, et al. Indications and outcomes of vitrectomy surgery in a series of 1000 black African eyes. BMJ Open Ophthalmol. 2019 28;4(1):e000083.
Amissah-Arthur KN, Mensah E. The past, present and future management of sickle cell retinopathy within an African context. Eye (Lond). 2018;32(8):1304-14.
Myint KT, Sahoo S, Thein AW, Moe S, Ni H. Laser therapy for retinopathy in sickle cell disease. Cochrane Database Syst Rev. 2015;(10):CD010790.
Williamson TH, Rajput R, Laidlaw DA, Mokete B. Vitreoretinal management of the complications of sickle cell retinopathy by observation or pars plana vitrectomy. Eye (Lond). 2009;23(6):1314-20.
- Abstract Viewed: 202 times
- PDF Downloaded: 105 times
